| __timestamp | Apellis Pharmaceuticals, Inc. | Bausch Health Companies Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 2026300000 |
| Thursday, January 1, 2015 | 6356782 | 2682700000 |
| Friday, January 1, 2016 | 4303743 | 2810000000 |
| Sunday, January 1, 2017 | 10463151 | 2582000000 |
| Monday, January 1, 2018 | 22639184 | 2473000000 |
| Tuesday, January 1, 2019 | 67046483 | 2554000000 |
| Wednesday, January 1, 2020 | 139401000 | 2367000000 |
| Friday, January 1, 2021 | 176771000 | 2624000000 |
| Saturday, January 1, 2022 | 277163000 | 2625000000 |
| Sunday, January 1, 2023 | 500815000 | 2917000000 |
Infusing magic into the data realm
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Apellis Pharmaceuticals, Inc. and Bausch Health Companies Inc. offer a fascinating study in contrasts. From 2014 to 2023, Apellis saw a staggering increase in SG&A expenses, growing from approximately $2.9 million to over $500 million, a rise of over 17,000%. Meanwhile, Bausch Health's SG&A costs remained relatively stable, fluctuating around $2.5 billion annually, with a modest increase of about 44% over the same period.
This data highlights Apellis's rapid expansion and investment in administrative capabilities, while Bausch Health maintains a steady approach. Investors and analysts should consider these trends when evaluating the operational efficiency and strategic priorities of these companies. Understanding how each company manages its SG&A expenses can provide insights into their long-term financial health and market strategies.
Operational Costs Compared: SG&A Analysis of Amgen Inc. and Bausch Health Companies Inc.
Cost Management Insights: SG&A Expenses for Regeneron Pharmaceuticals, Inc. and Bausch Health Companies Inc.
SG&A Efficiency Analysis: Comparing BeiGene, Ltd. and Bausch Health Companies Inc.
Insmed Incorporated or Bausch Health Companies Inc.: Who Manages SG&A Costs Better?
Ascendis Pharma A/S or Bausch Health Companies Inc.: Who Manages SG&A Costs Better?
Grifols, S.A. vs Bausch Health Companies Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Ionis Pharmaceuticals, Inc. vs Bausch Health Companies Inc.
Cost Management Insights: SG&A Expenses for Apellis Pharmaceuticals, Inc. and Perrigo Company plc
SG&A Efficiency Analysis: Comparing Apellis Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc.
Viking Therapeutics, Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Bausch Health Companies Inc. or Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Bausch Health Companies Inc. or MiMedx Group, Inc.